EAST HANOVER, N.J., Sept. 30, 2025 /PRNewswire/ -- Novartis announced today that Rhapsido ® (remibrutinib) received US Food and Drug Administration (FDA) approval as an oral treatment for adult ...

Please provide your email address to receive an email when new articles are posted on . The approval of the Bruton tyrosine kinase inhibitor for chronic idiopathic urticaria, also known as chronic ...

Novartis (NYSE:NVS) is one of the best growth stocks to buy now. On September 30, Novartis announced the US FDA approval of its drug, Rhapsido (remibrutinib). This oral pill is approved for use in ...

Urticaria symptom reduction with remibrutinib was linked with improved quality of life and sleep for patients with chronic spontaneous urticaria. One of the things that comes across in every chronic ...

Selumetinib was approved for NF1 in children as young as 1, expanding its use to younger patients with inoperable tumors. Ruxolitinib cream received approval for atopic dermatitis in children aged 2 ...

As treatment options have expanded for the treatment of chronic spontaneous urticaria (CSU), the question of which one works best has gained importance. The anti-immunoglobulin E (IgE) antibody ...

Rhapsido helps to inhibit release of histamine and proinflammatory mediators by targeting BTK, offering unique approach to CSU treatment 1 Well-controlled disease observed as fast as two weeks, with ...

"The approval of remibrutinib is an important development in CSU care. It quickly reduces symptoms, offering patients control of the hives and itching that they experience on a daily basis," said ...